Susan M. Galli
Susan is a partner in the life sciences and intellectual property transactions practice groups. She focuses her practice on advising pharmaceutical, biotech, medical device and other technology companies on licensing, collaboration and research agreements, joint ventures, asset acquisitions and divestitures, and other major transactions. Susan also advises research institutions on developing vehicles for translational research and on structuring transactions with industry, the government and other institutions.
- Represented Alexion Pharmaceuticals in a strategic collaboration with Blueprint Medicines to discover, develop and commercialize novel drug candidates for rare genetic diseases.
- Represented Pfizer Inc. in connection with its Centers for Therapeutic Innovations and transactions for its Global Biotherapeutics, Rare Disease and Immunoscience units.
- Represented Harvard University and the Broad Institute in connection with their exclusive license in the field of human therapeutics to Cambridge-based start-up Editas Medicine.
- Represented Children’s Hospital of Philadelphia (CHOP) in a research collaboration and license agreement with Medgenics that focuses on the development of new therapies for rare and orphan pediatric diseases.
- Represented Massachusetts General Hospital and the Broad Institute in a strategic collaboration with Amgen to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease.
- Represented AstraZeneca in its collaboration agreement with Theravance in the anesthesia field.
- Represented the Broad Institute in its collaborations with Roche, Bayer and AstraZeneca and its license with Verastem.
- Represented Psivida, an ophthalmics company, in its collaboration and license agreements with Bausch & Lomb, Pfizer and Alimera.
- Represented device companies Percardia and Eleme in numerous license, research, distributor and supply agreements.
- Represented AGTC in its collaboration agreement with Genzyme and agreements with universities.
- Represented Genzyme in a collaboration agreement with the Broad Institute.
- Represented venture-backed biotechnology, device and engineering spin-offs from research institutions including Harvard, MIT, UCLA and MGH.